Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1**Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors1Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to the US Food and Drug Administration (FDA) for chronic ...

Core Insights - The company reported a 19% increase in net sales for Q1 2025 compared to Q1 2024, reaching DKK 78.1 billion, with operating profit rising by 22% to DKK 38.8 billion [2][3] - The company has revised its full-year sales growth outlook to 13-21% at constant exchange rates (CER), down from previous expectations due to lower-than-planned penetration of branded GLP-1 treatments in the US [3][4] Financial Performance - Net sales for Q1 2025 were DKK 78,087 million, up from DKK 65,349 million in Q1 2024, reflecting a growth of 19% [2] - Operating profit increased to DKK 38,791 million, a 22% rise from DKK 31,846 million in the previous year [2] - Net profit for the quarter was DKK 29,034 million, a 14% increase from DKK 25,407 million in Q1 2024 [2] - Diluted earnings per share rose to DKK 6.53, up 15% from DKK 5.68 [2] Sales Breakdown - Sales in US Operations grew by 20% in Danish kroner and 17% at CER, while International Operations saw an 18% increase in Danish kroner and 19% at CER [4] - Sales in Diabetes and Obesity care increased by 21% to DKK 73.5 billion, driven by a 67% growth in Obesity care to DKK 18.4 billion [4] - GLP-1 diabetes sales grew by 13% in Danish kroner and 11% at CER, while Rare disease sales increased by 5% in Danish kroner and 3% at CER [4] Research and Development - The company completed the REDEFINE 2 trial for CagriSema, showing a weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes [4] - The company has submitted oral semaglutide 25 mg for regulatory review to the US FDA, aiming to be the first oral GLP-1 treatment for obesity [4] - Regulatory submissions for once-weekly semaglutide 2.4 mg have been made in both the EU and US, with priority review granted in the US [4] Outlook - The updated sales growth outlook for 2025 is now expected to be 3 to 5 percentage points lower than previously anticipated when reported in Danish kroner [4] - The company is focused on addressing the challenges posed by compounded GLP-1 treatments in the US and expanding access to its products [3][4]